Barclays
ANRO icon

Barclays’s Alto Neuroscience ANRO Stock Holding History

Barclays’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Sell
13,318
-11,718
-47% -$271K ﹤0.01% 3395
2026
Q1 		$563K Sell
25,036
-5,356
-18% -$99.3K ﹤0.01% 3127
2025
Q4 		$541K Buy
30,392
+30,350
+72,262% +$382K ﹤0.01% 3798
2025
Q3 		$169 Buy
42
+41
+4,100% +$136 ﹤0.01% 5248
2025
Q2 		$2 Sell
1
-22,507
-100% -$53.6K ﹤0.01% 5192
2025
Q1 		$48.6K Sell
22,508
-17,299
-43% -$61.9K ﹤0.01% 4617
2024
Q4 		$168K Buy
39,807
+10,208
+34% +$63.7K ﹤0.01% 4383
2024
Q3 		$339K Buy
29,599
+26,556
+873% +$325K ﹤0.01% 4013
2024
Q2 		$32.5K Sell
3,043
-2,861
-48% -$37.2K ﹤0.01% 4345
2024
Q1 		$90.6K Buy
+5,904
New +$92.4K ﹤0.01% 4465

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Barclays's ANRO Position: Q2 2026 in Review

Barclays reduced its Alto Neuroscience (ANRO) stake by 47% in Q2 2026, selling an estimated $271K and leaving 13,318 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #3395.

Barclays first reported a position in ANRO in Q1 2024 and has held it in 10 quarters since. The position peaked at $563K in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Barclays held 13,318 shares of Alto Neuroscience worth $351K as of Q2 2026.
  • Barclays sold 11,718 Alto Neuroscience shares in Q2 2026, an estimated $271K.
  • Alto Neuroscience made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3395 holding.
  • Barclays first reported a position in Alto Neuroscience in Q1 2024 and has held it in 10 quarters since.
  • Barclays's Alto Neuroscience position peaked at $563K in Q1 2026.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.